Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses developments in oral contraceptives, highlighting improved individualization, reduced side effects, and enhanced suitability for various women's health needs, but it reports no new clinical results.

The authors reported that both finasteride and oral contraceptives with drospirenone had a significant therapeutic effect on women with polycystic ovary syndrome, leading to pregnancies in both treatment groups.

The estradiol valerate/dienogest oral contraceptive helps with heavy periods, may improve acne and symptoms in PCOS, and doesn't affect sexual function.

This systematic review concluded that the support for using spironolactone at commonly prescribed doses is based on evidence of limited quality.

This study identified 26 bioactive compounds in the ethanol extract of Indigofera tinctoria leaves, which are linked to various therapeutic activities, supporting its traditional medicinal use in treating numerous health conditions.

This case series suggests that EE/CMA 0.03mg/2mg may help manage dermatological disorders related to androgen excess, as evidenced by symptomatic improvements in the four patients treated.

This publication discusses the political rationale behind the French regulator ANSM's decision to withdraw Diane®-35 from the market, in response to health concerns associated with third-generation oral contraceptives.

This review discusses existing literature on the effects of isoflavone in alleviating PCOS symptoms, highlighting its potential benefits in reducing testosterone levels, improving metabolic profiles, and lowering inflammation and oxidative stress, although findings have been both significant and non-significant.

Hormonal contraceptives are effective for teens but require careful consideration of side effects and individual health.

This review discusses the historical development, mechanisms of action, and potential new clinical applications of the drug cepharanthine, highlighting its multi-faceted pharmacological properties; it reports no new clinical results.

This review discusses the diagnostic criteria and treatment options for polycystic ovary syndrome focusing on metabolic subtypes and reports no clinical results.

This study concluded that combined hormonal contraceptives containing desogestrel, drospirenone, or cyproterone acetate were associated with a higher risk of venous thromboembolism compared to those containing levonorgestrel.

This review discusses the relationship between SHBG, NAFLD, and PCOS and reports no new clinical results; the authors highlight low hepatic SHBG production as potentially significant in PCOS pathogenesis.

This review discusses the symptoms, diagnosis, and current treatment recommendations for polycystic ovary syndrome, noting that many women may remain undiagnosed and at risk for complications.

This article reviews the hormonal pathogenesis and treatment strategies for acne vulgaris, particularly in women with severe or treatment-resistant cases, associating it with hormonal imbalances and hyperandrogenism.

Among obese women potentially eligible for combined oral contraceptives, this study observed a higher frequency of non-alcoholic fatty liver disease in those with polycystic ovary syndrome.

This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.

This study found that in Chinese women with PCOS, pretreatment with ethinylestradiol/cyproterone acetate was associated with a lower risk of gestational diabetes, pregnancy-induced hypertension, and premature delivery compared to those without pretreatment.

This study concluded that alopecia is a rare side effect of SSRIs, with sertraline showing a higher association compared to citalopram, particularly among women.

This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.

This article reviews the use of hormonal therapies in dermatology, specifically focusing on their pathophysiologic rationale, indications, commonly used drugs, and pretreatment evaluations, and it reports no new research findings.

This review discusses the pathophysiology, diagnosis, and management of functional hypothalamic amenorrhea in adolescent girls and reports no new clinical results.

This systematic review identified several factors contributing to increased cardiovascular risk in women with polycystic ovary syndrome, including insulin resistance, obesity, inflammation markers, and microbiota alterations linked to elevated trimethylamine-N-oxide levels.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This review discusses the use of hormonal therapies for managing acne vulgaris in adult women and reports no new clinical results, emphasizing the chronic and severe nature of acne in this population.

This review discusses the role of dermatologists in diagnosing and treating PCOS-related dermatological manifestations, emphasizing the importance of early intervention to enhance patients' quality of life, but reports no new clinical findings.

In this review, spironolactone is highlighted for its emerging use in dermatology, particularly for treating androgen-mediated conditions like acne and hirsutism in susceptible females, though it requires careful monitoring for potential adverse effects.

This review outlines the complexities and varied manifestations of polycystic ovary syndrome, highlighting challenges in diagnosis and management but reports no new clinical findings.

This study suggests that lower-dose ethinyl estradiol formulations and progestin-only contraceptives may offer safer options for managing PCOS in obese women due to minimal metabolic effects.

This review discusses the association between polycystic ovarian syndrome and hypertension, highlighting evidence of metabolic factors influencing this potential link and stressing the need for further research in this area.